FGFR2 and cholangiocarcinoma: Consistent with results in FGFR2 fusion–expressing NIH3T3 cells, treatment of the ICC13-7 cholangiocarcinoma cell line with bpAb-B/C and bpAb-B/D led to increases in fluorescent signals compared with parental antibodies (Figure 6I).